Irina Chazova

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7095886/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal, 2018, 39, 3021-3104.	1.0	6,826
2	Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension. New England Journal of Medicine, 2013, 369, 809-818.	13.9	1,168
3	Riociguat for the Treatment of Pulmonary Arterial Hypertension. New England Journal of Medicine, 2013, 369, 330-340.	13.9	1,120
4	Selexipag for the Treatment of Pulmonary Arterial Hypertension. New England Journal of Medicine, 2015, 373, 2522-2533.	13.9	790
5	Olmesartan for the Delay or Prevention of Microalbuminuria in Type 2 Diabetes. New England Journal of Medicine, 2011, 364, 907-917.	13.9	741
6	Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. New England Journal of Medicine, 2016, 374, 2021-2031.	13.9	641
7	Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease. New England Journal of Medicine, 2016, 374, 2009-2020.	13.9	526
8	Pulmonary hypertension due to left heartÂdisease. European Respiratory Journal, 2019, 53, 1801897.	3.1	389
9	Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease. New England Journal of Medicine, 2016, 374, 2032-2043.	13.9	299
10	Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. Lancet, The, 2010, 376, 517-523.	6.3	222
11	Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies. Lancet Neurology, The, 2011, 10, 43-53.	4.9	177
12	Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial. International Journal of Clinical Practice, 2010, 64, 1619-1631.	0.8	146
13	Diet and Kidney Disease in High-Risk Individuals With Type 2 Diabetes Mellitus. JAMA Internal Medicine, 2013, 173, 1682-92.	2.6	100
14	Efficacy and safety of canagliflozin when used in conjunction with incretinâ€mimetic therapy in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2016, 18, 82-91.	2.2	74
15	Venous and arterial changes in pulmonary veno-occlusive disease, mitral stenosis and fibrosing mediastinitis. European Respiratory Journal, 2000, 15, 116-122.	3.1	65
16	Moxonidine improves glycaemic control in mildly hypertensive, overweight patients: a comparison with metformin. Diabetes, Obesity and Metabolism, 2006, 8, 456-465.	2.2	63
17	Blood pressure and other determinants of new-onset atrial fibrillation in patients at high cardiovascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with	0.3	57
18	Design, history and results of the Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) randomised controlled trial. Diabetologia, 2012, 55, 36-45.	2.9	56

IRINA CHAZOVA

#	Article	IF	CITATIONS
19	Improved Hypertension Control with the Imidazoline Agonist Moxonidine in a Multinational Metabolic Syndrome Population: Principal Results of the MERSY Study. International Journal of Hypertension, 2013, 2013, 1-9.	0.5	46
20	Oxidative stress in patients with primary pulmonary hypertension. Bulletin of Experimental Biology and Medicine, 2002, 133, 580-582.	0.3	38
21	Comparison of single-pill strategies first line in hypertension. Journal of Hypertension, 2015, 33, 401-411.	0.3	37
22	Overweight and Obesity in the Russian Population: Prevalence in Adults and Association with Socioeconomic Parameters and Cardiovascular Risk Factors. Obesity Facts, 2019, 12, 103-114.	1.6	31
23	Metabolically healthy obese and metabolically unhealthy non-obese phenotypes in a Russian population. European Journal of Epidemiology, 2017, 32, 251-254.	2.5	28
24	Novel Approaches in Primary Cardiovascular Disease Prevention: The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics. Canadian Journal of Cardiology, 2016, 32, 311-318.	0.8	24
25	Platelet aggregation in patients with primary pulmonary hypertension. Blood Coagulation and Fibrinolysis, 1996, 7, 225-227.	0.5	20
26	Real-life safety and effectiveness of amlodipine/valsartan combination in the treatment of hypertension. Advances in Therapy, 2011, 28, 134-149.	1.3	19
27	Effects on office and home blood pressure of the lercanidipine-enalapril combination in patients with Stage 2 hypertension. Journal of Hypertension, 2014, 32, 1700-1707.	0.3	19
28	Randomized evaluation of a novel, fixed-dose combination of perindopril 3.5 mg/amlodipine 2.5 mg as a first-step treatment in hypertension. Journal of Hypertension, 2015, 33, 653-662.	0.3	16
29	Effects of the lercanidipine–enalapril combination vs. the corresponding monotherapies on home blood pressure in hypertension. Journal of Hypertension, 2016, 34, 139-148.	0.3	10
30	Multiple rare and common variants in APOB gene locus associated with oxidatively modified low-density lipoprotein levels. PLoS ONE, 2019, 14, e0217620.	1.1	9
31	EURASIAN ASSOCIATION OF CARDIOLOGY (EAC) GUIDELINES FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES IN PATIENTS WITH DIABETES AND PREDIABETES (2021). Eurasian Heart Journal, 2021, , 6-61.	0.2	9
32	Russian Medical Society for Arterial Hypertension Expert Consensus: Hypertension and COVID-19. Systemic Hypertension, 2020, 17, 35-41.	0.1	9
33	Clinical practice guidelines on the diagnosis and treatment of patients with arterial hypertension and chronic obstructive pulmonary disease. Systemic Hypertension, 2020, 17, 7-34.	0.1	9
34	Russian medical society on arterial hypertension (RMSAH) Consensus of Experts on the use of radiofrequency denervation of the renal arteries in patients with arterial hypertension. Systemic Hypertension, 2020, 17, 7-18.	0.1	8
35	COMPLAINTS ON SLEEP BREATHING DISORDER AND CARDIOVASCULAR RISK FACTORS IN RUSSIAN REGIONS: DATA FROM ESSE-RF STUDY. Russian Journal of Cardiology, 2018, , 152-158.	0.4	8
36	May Measurement Month 2017 in Russia: hypertension treatment and control—Europe. European Heart Journal Supplements, 2019, 21, D101-D103.	0.0	6

IRINA CHAZOVA

#	Article	IF	CITATIONS
37	Features of antihypertensive therapy and real-world prescription of selective imidazoline receptor agonists in Russia vs other countries: STRAIGHT study data analysis. Terapevticheskii Arkhiv, 2021, 93, 440-448.	0.2	6
38	Characteristics of patients with chronic thromboembolic pulmonary hypertension according to the Russian National Registry. Terapevticheskii Arkhiv, 2021, 93, 1058-1065.	0.2	6
39	Pulmonary capillary haemangiomatosis coexistence with sinus venosus ASD: morphometric analysis and literature review. European Respiratory Journal, 1998, 12, 240-244.	3.1	5
40	Radiofrequency renal denervation with mono-electrode and multi-electrode device for treatment in patient with uncontrolled hypertension: results of a 6-month follow-up. Systemic Hypertension, 2020, 17, 46-50.	0.1	5
41	Optimization of specific therapy for pulmonary hypertension: the possibilities of riociguat. Terapevticheskii Arkhiv, 2021, 93, 1117-1124.	0.2	5
42	Expert consensus. Effect of antihypertensive therapy on cognitive functions. Systemic Hypertension, 2021, 18, 5-12.	0.1	4
43	Myocardial perfusion in patients with pulmonary hypertension of different etiology. , 2015, , .		4
44	The incidence of cardiovascular and cerebrovascular complications in patients with uncontrolled hypertension. Terapevticheskii Arkhiv, 2022, 94, 94-99.	0.2	4
45	Comparative genetic analysis of different forms of low-renin arterial hypertension. Molecular Biology, 2008, 42, 521-530.	0.4	3
46	Uncontrolled arterial hypertension: main causes, features of pathogenesis and approaches to treatment. Systemic Hypertension, 2021, 18, 13-18.	0.1	3
47	Pulmonary arterial hypertension: achievements and realities of modern treatment, a look into the future. Terapevticheskii Arkhiv, 2021, 93, 1009-1017.	0.2	3
48	Impact of metabolic syndrome parameters and different fat depots on arterial stiffness in patients with abdominal obesity. Systemic Hypertension, 2020, 17, 55-62.	0.1	2
49	Gender-age peculiarities of smoking and diabetes mellitus role in the development of myocardial infarction in patients with arterial hypertension. Systemic Hypertension, 2020, 17, 24-31.	0.1	2
50	Assessment of epicardial adipose tissue by echocardiography for risk stratification in young adults with abdominal obesity. Systemic Hypertension, 2020, 17, 74-79.	0.1	2
51	Experience with various occluder types for endovascular hemodynamic isolation of the left atrium appendage in patients with non-valvular atrial fibrillation. Journal of Arrhythmology, 2021, 28, 45-54.	0.1	2
52	The value of cardiopulmonary exercise test in assessment of the severity of pulmonary arterial hypertension patients. , 2017, , .		2
53	Evaluation of serum cytokines in patients with idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension with hypercholesterolemia. , 2017, , .		2
54	Antecubital vein access for balloon pulmonary angioplasty in patients with chronic thromboembolic pulmonary hypertension: safe new approach. Russian Open Medical Journal, 2019, 8, e0107.	0.1	2

Irina Chazova

#	Article	IF	CITATIONS
55	Hybrid approach for treating patient with chronic thromboembolic pulmonary hypertension and extrinsic compression of left main coronary artery. Russian Open Medical Journal, 2019, 8, .	0.1	2
56	Management of patients with arterial hypertension and atrial fibrillation. Systemic Hypertension, 2021, 18, 105-128.	0.1	2
57	Efficacy and safety of azilsartan medoxomil in various doses in patients with metabolic disorders. Systemic Hypertension, 2021, 18, 130-139.	0.1	2
58	Clinical features and course of arterial hypertension in patients with its various forms. Systemic Hypertension, 2021, 18, 140-146.	0.1	2
59	Treatment of patients with arterial hypertension in clinical practice in 2010–2020 (according to the) Tj ETQq1 I	0.78431 0.2	4 ggBT /Over
60	Interrelation of the damage of the target organs in patients with arterial hypertension in presence or absence of the metabolic syndrome. International Journal of Cardiology, 2009, 137, S55.	0.8	1
61	Special features of renal damage in arterial hypertension in presence and absence of metabolic syndrome. International Journal of Cardiology, 2009, 137, S57-S58.	0.8	1
62	Changes in the receptor activity of β2-adrenoreceptors of human T-lymphocytes under the effect of β2-agonists. Molecular Biology, 2016, 50, 880-886.	0.4	1
63	Influence of demographic characteristics on the clinical course and results of therapy in patients with precapillary pulmonary hypertension. Terapevticheskii Arkhiv, 2021, 93, 283-289.	0.2	1
64	The effect of adherence with long-term PAP therapy on the psycho-emotional state of patients with obstructive sleep apnea syndrome. Systemic Hypertension, 2020, 17, 56-60.	0.1	1
65	Left ventricular-arterial coupling and cardiac remodeling in patients with idiopathic arterial pulmonary hypertension. , 2015, , .		1
66	Sleep duration and cardiovascular risk: results of the large-scale epidemiology study ESSE-RF. Arterial Hypertension, 2019, 23, 248-255.	0.2	1
67	Long-term positive airway pressure therapy in patients with various forms of atrial fibrillation and obstructive sleep apnea. Kardiologicheskii Vestnik, 2020, , 72-78.	0.1	1
68	STRUCTURAL CHANGES OF THE PULMONARY ARTERIES AFTER BALLOON PULMONARY ANGIOPLASTY IN PATIENTS WITH CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION. Eurasian Heart Journal, 2020, , 12-20.	0.2	1
69	First results of Russian multicenter prospective clinical study VICTORY II: Vamloset® and Co-Vamloset effectiveness and safety in patients with stage 2 and 3 arterial hypertension. Systemic Hypertension, 2020, 17, 36-47.	0.1	1
70	Parameters of acute vasoreactivity testing after balloon pulmonary angioplasty in patients with chronic thromboembolic pulmonary hypertension. Systemic Hypertension, 2020, 17, 53-58.	0.1	1
71	The assessment of renal function during the therapy of arterial hypertension with azilsartan medoxomil in patients with obesity or overweight and concomitant metabolic disorders. Terapevticheskii Arkhiv, 2021, 93, 1510-1515.	0.2	1
72	Intima-media thickness of common carotid artery in patients with arterial hypertension and in presence or absence of metabolic syndrome. International Journal of Cardiology, 2009, 137, S57.	0.8	0

IRINA CHAZOVA

#	Article	IF	CITATIONS
73	СPAP-therapy decrease arterial stiffness in patients with arterial hypertension and obstructive sleep apnea. International Journal of Cardiology, 2009, 137, S133.	0.8	0
74	PAP-therapy adherence in patients with obstructive sleep apnea and cardiovascular diseases. Systemic Hypertension, 2020, 17, 37-43.	0.1	0
75	Efficacy and safety of using a fixed-dose combination of azilsartan medoxomil and chlorthalidone in patients with diabetes mellitus. Systemic Hypertension, 2020, 17, 68-73.	0.1	0
76	Aspects of efficacy, safety and adherence to antihypertensive therapy with single pill combinations of valsartan, amlodipine and hydrochlorothiazide (Vamloset® and Co-Vamloset) in patients with 2 and 3 grade of arterial hypertension in the Russian clinical study VICTORY II. Systemic Hypertension, 2021, 18, 50-62.	0.1	0
77	From palpation of the pulse to cuff-free methods: evolution of arterial pressure measurement methods. Terapevticheskii Arkhiv, 2021, 93, 526-531.	0.2	0
78	Consensus of experts from the Russian Medical Society of Arterial Hypertension. Arterial hypertension and erectile dysfunction. Systemic Hypertension, 2021, 18, 69-79.	0.1	0
79	The clinical case of successful combined treatment of refractory arterial hypertension. Case report. Terapevticheskii Arkhiv, 2021, 93, 1086-1090.	0.2	0
80	Cardiac remodeling and left ventricular-arterial coupling in patients with chronic thromboembolic pulmonary hypertension. , 2015, , .		0
81	The method of evaluation of \hat{I}^2 -receptor's activity changes. , 2015, , .		0
82	Antecubital venous access for balloon pulmonary angioplasty in patients with chronic thromboembolic pulmonary hypertension. , 2016, , .		0
83	Thermodilution and Fick cardiac output measurement comparison in patients with pulmonary hypertension. , 2017, , .		0
84	Arterial hypertension in elderly and senile patients: clinical characteristics and treatment quality (according to the national register of arterial hypertension). Siberian Medical Journal, 2019, 34, 73-86.	0.3	0
85	Pulmonary hypertension in a patient with kyphoscoliotic heart disease. Siberian Medical Journal, 2019, 34, 172-178.	0.3	0
86	Speckle-tracking echocardiography in 3D mode in assessing the deformation of the myocardium and identifying subclinical cardiotoxicity during chemotherapy in breast cancer patients with arterial hypertension. Systemic Hypertension, 2020, 17, 42-47.	0.1	0
87	Implementation of the organoprotective properties of fixed combinations of valsartan, amlodipine and hydrochlorothiazide (Vamloset® and Co-Vamloset) in patients with grade 2 and 3 hypertension in the Russian clinical study VICTORY II. Systemic Hypertension, 2020, 17, 59-70.	0.1	0
88	COVID-19: a patient with cardiovascular disease at high risk. Systemic Hypertension, 2020, 17, 76-83.	0.1	0
89	Role of cardiac computed tomography in endovascular isolation of the left atrial appendage. Kardiologiya I Serdechno-Sosudistaya Khirurgiya, 2022, 15, 46.	0.1	0
90	The impact of left atrial appendage occlusion on the rhythm control in atrial fibrillation: a prospective cohort study. Kardiologicheskii Vestnik, 2022, 17, 73.	0.1	0